“aimmune-therapeutics” Archives

in
Entry Author Date Location
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More 09/04/20 National
Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal 08/31/20 San Francisco
IgGenix Grabs $10M to Advance Antibody Treatments for Allergies 08/05/20 San Francisco
Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch 08/04/20 National
With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash 06/26/20 National
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More 03/27/20 National
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing 03/24/20 National
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy 01/31/20 San Francisco
Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA 09/13/19 San Francisco
FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb 09/11/19 San Francisco
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead 02/13/19 National
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More 01/25/19 National
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More 11/16/18 National
Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More 02/23/18 National
Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned 02/20/18 San Francisco
15 For ’18: Key Clinical Data to Watch For Next Year (Part 2) 12/06/17 National
RA Capital Seeds Peanut Allergy Prevention Startup With $1.7M 06/01/16 Boston
Aimmune Prices Upsized $160M IPO, Climbs Higher in Debut 08/06/15 San Francisco
Page 1 of 1